Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
There are currently several recommended drug regimens for uncomplicated falciparum malaria in Africa. Each has different properties that determine its impact on disease burden. Two major antimalarial policy options are artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DHA–PQP). Clinical trial data show that DHA–PQP provides longer protection against reinfection, while AL is better at reducing patient infectiousness. Here we incorporate pharmacokinetic-pharmacodynamic factors, transmission-reducing effects and cost into a mathematical model and simulate malaria transmission and treatment in Africa, using geographically explicit data on transmission intensity and seasonality, population density, treatment access and outpatient costs. DHA–PQP has a modestly higher estimated impact than AL in 64% of the population at risk. Given current higher cost estimates for DHA–PQP, there is a slightly greater cost per case averted, except in areas with high, seasonally varying transmission where the impact is particularly large. We find that a locally optimized treatment policy can be highly cost effective for reducing clinical malaria burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DHA/PPQ with its longer prophylactic tail has been modelled to be more cost-effective and superior in reducing clinical incidence and malaria prevalence than AL as first-line treatment in higher transmission settings; however, its impact in lower transmission settings like Ethiopia is less clear [45, 46].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Griffin, J. T., Hollingsworth, T. D., Okell, L. C., Churcher, T. S., White, M., Hinsley, W., Bousema, T., Drakeley, C. J., Ferguson, N. M., Basáñez, M.-G., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000324 · Cited by 595
Self-citationTarning, J., Rijken, M. J., McGready, R., Phyo, A. P., Hanpithakpong, W., Day, N. P. J., White, N. J., Nosten, F., & Lindegardh, N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05756-11 · Cited by 102
Tarning, J., McGready, R., Lindegardh, N., Ashley, E. A., Pimanpanarak, M., Kamanikom, B., Annerberg, A., Day, N. P. J., Stepniewska, K., Singhasivanon, P., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-09 · Cited by 99
Research works printed but not linked: 47
- World Health Organization. WHO Guidelines for the Treatment of Malaria 2nd edn WHO Press (2010).
- Smith, D. L., Klein, E. Y., McKenzie, F. E. & Laxminarayan, R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar. J. 9, 217 (2010). · DOI
- The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 8, e1000402 (2011). · DOI · Paper page
- Okell, L. C., Drakeley, C. J., Bousema, T., Whitty, C. J. & Ghani, A. C. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 5, e226 (2008). · DOI · Paper page
- Cairns, M. et al. Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children. PLoS ONE 6, e18947 (2011). · DOI
- Kumar, N. & Zheng, H. Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol. Res. 76, 214–218 (1990). · DOI
- Tarning, J. et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin. Pharmacol. Ther. 91, 497–505 (2012). · doi:10.1038/clpt.2011.254
- Pfeil, J., Borrmann, S. & Tozan, Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS ONE 9, e95681 (2014). · DOI · Paper page
- Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 8, e1001119 (2011). · DOI
- Sawa, P. et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J. Infect. Dis. 207, 1637–1645 (2013). · DOI
- van Pelt-Koops, J. C. et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544–3548 (2012). · DOI
- Adjalley, S. H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108, E1214–E1223 (2011). · DOI · Paper page
- Bassat, Q. et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS ONE 4, e7871 (2009). · DOI · Paper page
- Zongo, I. et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin. Infect. Dis. 45, 1453–1461 (2007). · DOI
- WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 10, e1001564 (2013). · DOI · Paper page
- Sinclair, D., Zani, B., Donegan, S., Olliaro, P. & Garner, P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. CD007483 (2009). · DOI · Paper page
- Griffin, J. T., Ferguson, N. M. & Ghani, A. C. Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat. Commun. 5, 3136 (2014). · DOI · Paper page
- Bigira, V. et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial. PLoS Med. 11, e1001689 (2014). · DOI
- Gething, P. W. et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar. J. 10, 378 (2011). · DOI · Paper page
- Cairns, M. et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat. Commun. 3, 881 (2012). · DOI · Paper page
- Flaxman, A. D. et al. Rapid scaling up of insecticide-treated bed net coverage in Africa and its relationship with development assistance for health: a systematic synthesis of supply, distribution, and household survey data. PLoS Med. 7, e1000328 (2010). · DOI
- Cohen, J. M. et al. Public health. Optimizing investments in malaria treatment and diagnosis. Science 338, 612–614 (2012). · DOI · Paper page
- White, M. T., Conteh, L., Cibulskis, R. & Ghani, A. C. Costs and cost-effectiveness of malaria control interventions-a systematic review. Malar. J. 10, 337 (2011). · DOI · Paper page
- Conteh, L. et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS ONE 5, e10313 (2010). · DOI
- Conteh, L. et al. Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children. PLoS ONE 5, e12223 (2010). · DOI
- Dunyo, S. et al. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin. Trials 1, e20 (2006). · DOI · Paper page
- Okell, L. C., Drakeley, C. J., Ghani, A. C., Bousema, T. & Sutherland, C. J. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar. J. 7, 125 (2008). · DOI · Paper page
- Bousema, T. et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 9, 136 (2010). · DOI · Paper page
- White, N. J. How antimalarial drug resistance affects post-treatment prophylaxis. Malar. J. 7, 9 (2008). · DOI · Paper page
- Tran, T. H. et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363, 18–22 (2004). · DOI · Paper page
- Leang, R. et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 57, 818–826 (2013). · DOI · Paper page
- Amaratunga, C. et al. inAmerican Society of Tropical Medicine & Hygiene. 62nd Annual Meeting. Symposium 44: Artemisinin-Resistant Plasmodium falciparum Malaria: Latest Findings from Clinical Molecular and Behavioral Studies (2013).
- Hastings, I. M., Watkins, W. M. & White, N. J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Phil. Trans. R. Soc. Lond. B. Biol. Sci. 357, 505–519 (2002). · DOI · Paper page
- Basco, L. K., Bickii, J. & Ringwald, P. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrob. Agents Chemother. 42, 2347–2351 (1998). · doi:10.1128/aac.42.9.2347
- Denis, M. B. et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated Falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11, 1800–1807 (2006). · DOI · Paper page
- Song, J. et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar. J. 10, 231 (2011). · doi:10.1186/1475-2875-10-231
- Mace, K. E. et al. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin. Infect. Dis. 53, 772–779 (2011). · DOI · Paper page
- Ashley, E. A. et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12, 195–200 (2007). · DOI · Paper page
- Djimde, A. A. et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 55, 3994–3999 (2011). · DOI
- Mueller, I. et al. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc. Natl Acad. Sci. USA 109, 10030–10035 (2012). · DOI · Paper page
- Hermsen, C. C. et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol. Biochem. Parasitol. 118, 247–251 (2001). · DOI · Paper page
- Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S. & White, N. J. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44, 697–704 (2000). · DOI · Paper page
- Wanzira, H. et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin. Infect. Dis. 59, 509–516 (2014). · doi:10.1093/cid/ciu353
- De Beaudrap, P. et al. Heterogeneous decrease in malaria prevalence in children over a six-year period in south-western Uganda. Malar. J. 10, 132 (2011). · DOI · Paper page
- Hay, S. I. et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med. 6, e1000048 (2009). · DOI · Paper page
- Okell, L. C. et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE 6, e20179 (2011). · DOI · Paper page
- Chanda, P., Castillo-Riquelme, M. & Masiye, F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff. Resour. Alloc. 7, 5 (2009). · DOI
Cited by
Walker, P. G. T., Griffin, J. T., Ferguson, N. M., & Ghani, A. C. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30073-0 · Cited by 124
Self-citationAssefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., et al. (2022) · Malaria Journal · doi:10.1186/s12936-022-04350-z · Cited by 20
Metadata
- Authors
- Okell, L. C., Cairns, M., Griffin, J. T., Ferguson, N. M., Tarning, J., Jagoe, G., Hugo, P., Baker, M., D’Alessandro, U., Bousema, T., Ubben, D., & Ghani, A. C.
- Venue
- Nature Communications
- Published
- 2014-11-26
- Volume
- 5
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 91
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. https://app.cochat.ai/papers/10.1038/ncomms6606
- The paper
- Okell, L. C., Cairns, M., Griffin, J. T., Ferguson, N. M., Tarning, J., Jagoe, G., Hugo, P., Baker, M., D’Alessandro, U., Bousema, T., Ubben, D., & Ghani, A. C. (2014). Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nature Communications. https://doi.org/10.1038/ncomms6606
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.